TERPENICOL Antifungal Cream (Undecylenic Acid 13%) recall — Blaine Labs Inc (Class II)

Blaine Labs Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling TERPENICOL Antifungal Cream (Undecylenic Acid 13%) — a Class II recall, initiated 2026-04-08 and posted to the FDA enforcement report on 2026-07-08, under recall number D-0695-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry”. From the product description, the form is cream and the strengths given are 13%, 28 g and 11037 L. 1 National Drug Code number is printed in the record: 63347-601-01. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in CA, United States. The FDA files it under event ID 98731 together with 7 other recall numbers, all listed and linked below. Within that event this is the strength 13% · 28 g · 11037 L, form Cream and ndc 63347-601-01 configuration; the sibling records differ on strength, package, form and ndc, and 3 more and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0695-2026
FDA event ID 98731 (8 recall numbers)
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Blaine Labs Inc
Recall initiated 2026-04-08
Reported by FDA 2026-07-08
Report lag 91 days from initiation to report
Distribution Nationwide in the USA — Nationwide (US)
Firm location on record CA, United States
Product description (source) TERPENICOL Antifungal Cream (Undecylenic Acid 13%), 1.0 oz (28 g) bottles, Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Sante Fe Springs, CA 90670, NDC 63347-601-01.

Reason reported by FDA

CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry

16 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 26-word product description above; each is a literal substring of it.

Product named TERPENICOL Antifungal Cream (Undecylenic Acid 13%)
Form Cream
Strength 13% · 28 g · 11037 L
NDC 63347-601-01
Manufactured by Blaine Labs, Inc.

Which configuration this record is

8 recall numbers share event 98731. They differ on strength, package, form, ndc, product named, fda tier and reason text and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0695-2026) D-0692-2026D-0693-2026D-0694-2026D-0696-2026D-0697-2026D-0698-2026D-0699-2026
Strength 13% · 28 g · 11037 L 0.1% · 37 mL · 11037 L0.1% · 29.6 mL25% · 37.5 mL10% · 15 g · 11037 L25% · 29.6 mL · 11037 L25% · 11037 L0.1% · 16 mL · 85 g · 11037 L
Package 1.0 FL OZ (37 mL)1.0 fl oz1.25 FL OZ (37.5 mL)1.0 Fl Oz (29.6 mL)1.0 Fl OZ (16 mL) · 3.0 Fl OZ (85 g)
Form Cream GelGelSolutionCreamSolutionSolutionGel
NDC 63347-601-01 63347-120-0273352-520-0173352-550-0163347-600-0163347-120-02 · 63347-120-01
Product named TERPENICOL Antifungal Cream (Undecylenic Acid 13%) Revitaderm Wound Care GelTRIFLUENT PHARMA TRIDERGEL Wound Care GelTRIPENICOL S Antifungal Solution (Undecylenic Acid 25%)vite20 Antifungal CreamTERPENICOL Antifungal SolutionFungal Fusion ERADICATION SolutionRevitaderm Wound Care
FDA tier Class II Class IClass IIClass IIClass IIClass IIClass IIClass II
Reason text CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus sppCGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminatedCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryCGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated

Shared across all 8 records under this event: recalling firm Blaine Labs Inc; initiated 2026-04-08; reported 2026-07-08.

Event context: 8 recall numbers under event 98731

One enforcement action, 8 recall numbers: the FDA filed 7 further configurations of this action under event 98731. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
Revitaderm Wound Care Gel, 0.1%D-0692-2026Class I0.1% · Gel63347-120-022026-07-08
TRIFLUENT PHARMA TRIDERGEL Wound Care Gel, 0.1%D-0693-2026Class II0.1% · Gel73352-520-012026-07-08
TRIPENICOL S Antifungal Solution (Undecylenic Acid 25%)D-0694-2026Class II25% · Solution73352-550-012026-07-08
vite20 Antifungal Cream, 10%D-0696-2026Class II10% · Cream2026-07-08
TERPENICOL Antifungal Solution, 25%D-0697-2026Class II25% · Solution63347-600-012026-07-08
Fungal Fusion ERADICATION Solution, 25%D-0698-2026Class II25% · Solution2026-07-08
Revitaderm Wound Care, 0.1%D-0699-2026Class II0.1% · Gel63347-120-022026-07-08

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
BD ChloraPrep Hi-Lite Orange, 2%D-0643-2026Carefusion 213, LLCClass II2026-07-08
BD PurPrep, 8.3%D-0644-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Clear, 2%D-0645-2026Carefusion 213, LLCClass II2026-07-08
ChloraPrep FREPP, 2%D-0646-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Hi-Lite Orange, 2%D-0647-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Hi-Lite Orange, 2%D-0648-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Scrub Teal, 2%D-0649-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Scrub Teal, 2%D-0650-2026Carefusion 213, LLCClass II2026-07-08

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 1 nearest to 2026-07-08 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
BD ChloraPrep CLear, 2%D-0651-2026Carefusion 213, LLC2% · Solution2026-07-08

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 98731 returns all 8 of these recall numbers; a search on D-0695-2026 returns only this configuration. Match a package against 63347-601-01 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Blaine Labs Inc (8 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0695-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0695-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-08
Ingested
2026-08-22
Record hash
05ae1e2464a440ab

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.